Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Gbathaton Feb 27, 2023 9:23pm
137 Views
Post# 35308588

RE:Gbathat the second Boston Group mole is surfacing!!

RE:Gbathat the second Boston Group mole is surfacing!!$5 share price is what is needed to stay listed on Nasdaq.  So yes, the Boston group would probably have a strong interest in not letting the PPS fall below $5.

As posted multiple times, if you subtract the cash holdings of ABOS from their market cap, the valuation is similar to PMN, in my opinion.

Since ABOS is about a year ahead of PMN, PMN might actually be favored a bit. And I think that is because PMN has the better product.

Time will tell. If either company is successful, the returns could be massive.

And for the record, I have no affiliation with the Boston group, promis or acumen.  I just hold a couple thousand shares in PMN and Acumen.

Good luck to you.
<< Previous
Bullboard Posts
Next >>